Compare Brown-Forman Corporation Class B (BF.B) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brown-Forman Corporation Class B vs Mesoblast Limited — how do they compare? Brown-Forman Corporation Class B trades at $28.01, while Mesoblast Limited trades at $16.74 (market cap $2.21B). The key difference: Brown-Forman Corporation Class B is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| BF.B | MESO | |
|---|---|---|
Sector | Consumer Staples | Technology |
52-Week High | $31.26 | $20.96 |
52-Week Low | $22.80 | $12.88 |
Market Cap | — | $2.21B |
Enterprise Value | — | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BF.B trades at $27.92, down 0.96% with mixed technical signals showing bullish moving averages but neutral oscillators. The stock has demonstrated earnings momentum with three consecutive quarterly beats, though analyst coverage remains divided with a 25% buy rating. Recent price action shows consolidation around the $28 pivot point level.
The outlook remains cautiously optimistic given strong recent earnings performance, though limited analyst coverage and divided sentiment suggest moderate risk. Upside potential exists if earnings momentum continues, while downside risks include market volatility and potential execution challenges in maintaining growth trajectory.
MESO trades at $16.78, up 0.6% with a bullish technical signal from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144% net margin. Recent milestones include Phase 3 trial completion for chronic back pain and BLA filing for heart failure treatment, indicating pipeline progress.
Investment outlook balances promising commercial traction against significant financial losses. The stock offers growth potential from expanding indications but carries high risk due to negative earnings and dependence on regulatory approvals. Analyst consensus leans bullish with 45% buy ratings, though profitability remains the key challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brown-Forman Corporation Class B
Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.
Read more on BF.B →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
